Genetic Alterations Predict Long-Term Survival in Ductal Adenocarcinoma of the Pancreatic Head.
KRAS
NGS
PDAC
TP53
mutation
pancreatic cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Feb 2022
08 Feb 2022
Historique:
received:
27
12
2021
revised:
28
01
2022
accepted:
05
02
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Survival of patients with adenocarcinoma of the pancreas (PDAC) is poor and has remained almost unchanged over the past decades. The genomic landscape of PDAC has been characterized in recent years. The aim of this study was to identify a genetic profile as a possible predictor of prolonged survival in order to tailor therapy for PDAC patients. Panel next generation sequencing (NGS) and immunohistochemistry (IHC) were performed on paraffin-embedded tumor tissues from curatively treated PDAC patients. Tumor slides were re-evaluated with a focus on the histomorphology. Patients were subgrouped according to short and long overall (<4 years/>4 years) and disease-free (<2 years/>2 years) survival. Thirty-nine patients were included in the study. Clinicopathological staging variables as well as the histomorphological subgroups were homogenously distributed between short- and long-term overall and disease-free survivors. In survival analysis, patients with the NGS of PDAC revealed significant differences in survival outcome in a patient collective with homogenously distributed clinicopathological variables. Further multi-institutional studies are warranted to identify more long-term survivors to detect genetic differences suitable for targeted therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Survival of patients with adenocarcinoma of the pancreas (PDAC) is poor and has remained almost unchanged over the past decades. The genomic landscape of PDAC has been characterized in recent years. The aim of this study was to identify a genetic profile as a possible predictor of prolonged survival in order to tailor therapy for PDAC patients.
METHODS
METHODS
Panel next generation sequencing (NGS) and immunohistochemistry (IHC) were performed on paraffin-embedded tumor tissues from curatively treated PDAC patients. Tumor slides were re-evaluated with a focus on the histomorphology. Patients were subgrouped according to short and long overall (<4 years/>4 years) and disease-free (<2 years/>2 years) survival.
RESULTS
RESULTS
Thirty-nine patients were included in the study. Clinicopathological staging variables as well as the histomorphological subgroups were homogenously distributed between short- and long-term overall and disease-free survivors. In survival analysis, patients with the
CONCLUSIONS
CONCLUSIONS
NGS of PDAC revealed significant differences in survival outcome in a patient collective with homogenously distributed clinicopathological variables. Further multi-institutional studies are warranted to identify more long-term survivors to detect genetic differences suitable for targeted therapy.
Identifiants
pubmed: 35159117
pii: cancers14030850
doi: 10.3390/cancers14030850
pmc: PMC8833892
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Med. 2016 Sep;5(9):2649-56
pubmed: 27356493
Pancreatology. 2021 Jun;21(4):787-795
pubmed: 33775563
Cancers (Basel). 2017 Apr 28;9(5):
pubmed: 28452926
Cancer Biol Med. 2016 Mar;13(1):3-11
pubmed: 27144058
Cancer Biomark. 2018 Feb 6;21(2):323-334
pubmed: 29103024
Nat Genet. 2015 Oct;47(10):1168-78
pubmed: 26343385
Clin Cancer Res. 2015 Apr 15;21(8):1944-50
pubmed: 25623214
Cell. 2014 Apr 10;157(2):382-394
pubmed: 24725405
Langenbecks Arch Surg. 2018 Sep;403(6):693-700
pubmed: 30218193
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
J Clin Oncol. 2009 Apr 10;27(11):1806-13
pubmed: 19273710
Pancreas. 2012 May;41(4):541-6
pubmed: 22504380
Nat Rev Clin Oncol. 2013 Jun;10(6):323-33
pubmed: 23629472
Clin Transl Gastroenterol. 2016 Mar 24;7:e157
pubmed: 27010960
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Sci Rep. 2017 Feb 01;7:41064
pubmed: 28145465
Nature. 2017 Nov 23;551(7681):512-516
pubmed: 29132146
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Virchows Arch. 2018 Apr;472(4):519-531
pubmed: 29209757
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Nat Commun. 2015 Apr 09;6:6744
pubmed: 25855536
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Hepatobiliary Pancreat Dis Int. 2018 Oct;17(5):443-449
pubmed: 30126828
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Transl Gastroenterol Hepatol. 2019 Jun 27;4:50
pubmed: 31304427
Nat Commun. 2021 Mar 22;12(1):1808
pubmed: 33753749
Genes Dev. 2012 Jun 15;26(12):1268-86
pubmed: 22713868
Clin Cancer Res. 2012 Nov 15;18(22):6339-47
pubmed: 22991414
Nat Med. 2011 Apr;17(4):500-3
pubmed: 21460848
BMC Surg. 2021 Mar 3;21(1):110
pubmed: 33658016
Clin Cancer Res. 2020 Jul 15;26(14):3732-3739
pubmed: 32234756
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Cancer Sci. 2020 Jun;111(6):2174-2182
pubmed: 32314446
Clin Cancer Res. 2020 Mar 15;26(6):1385-1394
pubmed: 31871297
ESMO Open. 2021 Jun;6(3):100133
pubmed: 33984673
Ann Surg Oncol. 2008 Jun;15(6):1651-60
pubmed: 18351300
N Engl J Med. 2014 Nov 27;371(22):2140-1
pubmed: 25427123
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29229669
JAMA. 2007 Jan 17;297(3):267-77
pubmed: 17227978
Nature. 1986 Mar 6-12;320(6057):84-5
pubmed: 3456488
Ann Surg. 2018 Dec;268(6):1058-1068
pubmed: 28692477
Science. 2008 Sep 26;321(5897):1801-6
pubmed: 18772397
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
J Gastrointest Surg. 2008 Apr;12(4):701-6
pubmed: 18027062
Pancreas. 2008 Nov;37(4):352-7
pubmed: 18665012
Surgery. 2012 Sep;152(3 Suppl 1):S43-9
pubmed: 22763261